Opko Health (OPK) PT Lowered to $19 at Laidlaw after Trial Failure; 'Buy' Maintained

January 3, 2017 10:08 AM EST Send to a Friend
Laidlaw analyst Yale Jen lowered its price target on Opko Health (NASDAQ: OPK) to $19.00 (from $22.00) but maintained a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login